Silverback Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Silverback Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$293K	Sell	30,000 -35,000	-54%	-$304K	0.03%	64
2026 Q1	$362K	Buy	65,000 +25,000	+63%	+$191K	0.05%	57
2025 Q4	$294K	Hold	40,000	–	–	0.04%	56
2025 Q3	$262K	Sell	40,000 -30,000	-43%	-$161K	0.03%	62
2025 Q2	$302K	Buy	+70,000	New	+$343K	0.04%	62
2025 Q1	–	Hold	0	–	–	–	58

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Silverback Asset Management's KPTI Position: Q2 2026 in Review

Silverback Asset Management reduced its Karyopharm Therapeutics (KPTI) stake by 54% in Q2 2026, selling an estimated $304K and leaving 30,000 shares worth $293K. The position accounts for 0.03% of the portfolio, ranked #64.

Silverback Asset Management first reported a position in KPTI in Q2 2025 and has held it in 5 quarters since. The position peaked at $362K in Q1 2026. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Silverback Asset Management held 30,000 shares of Karyopharm Therapeutics worth $293K as of Q2 2026.
Silverback Asset Management sold 35,000 Karyopharm Therapeutics shares in Q2 2026, an estimated $304K.
Karyopharm Therapeutics made up 0.03% of Silverback Asset Management's portfolio in Q2 2026, its #64 holding.
Silverback Asset Management first reported a position in Karyopharm Therapeutics in Q2 2025 and has held it in 5 quarters since.
Silverback Asset Management's Karyopharm Therapeutics position peaked at $362K in Q1 2026.
96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Silverback Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.